Rise Advisors’s Tectonic Therapeutic TECX Stock Holding History

Rise Advisors’s Portfolio TECX Stock Details TECX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-28	Closed	-$439	–	1494
2025 Q3	$439	Hold	28	–	–	﹤0.01%	1440
2025 Q2	$556	Buy	+28	New	+$568	﹤0.01%	1390

Other funds holding TECX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Rise Advisors's TECX Position: Q4 2025 in Review

Rise Advisors sold out of Tectonic Therapeutic (TECX) in Q4 2025, closing a stake of 28 shares — an estimated $439 sold.

Rise Advisors first reported a position in TECX in Q2 2025 and held it in 2 quarters. The position peaked at $556 in Q2 2025. 105 funds tracked by Wall St. Rank hold TECX as of Q4 2025.

Rise Advisors reported no remaining Tectonic Therapeutic position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 28 Tectonic Therapeutic shares in Q4 2025, an estimated $439.
Rise Advisors first reported a position in Tectonic Therapeutic in Q2 2025 and held it in 2 quarters.
Rise Advisors's Tectonic Therapeutic position peaked at $556 in Q2 2025.
105 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.